Amgen Inc (AMGN): Today's Featured Drugs Laggard
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.7%. By the end of trading, Amgen fell $1.17 (-1.2%) to $97.49 on average volume. Throughout the day, 4,840,815 shares of Amgen exchanged hands as compared to its average daily volume of 3,826,500 shares. The stock ranged in price between $97.28-$101.72 after having opened the day at $100.20 as compared to the previous trading day's close of $98.66. Other companies within the Drugs industry that declined today were:
(
), down 38.6%,
(
), down 18.7%,
(
), down 13.5% and
(
), down 7.2%.
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $74.2 billion and is part of the health care sector. The company has a P/E ratio of 16.7, below the S&P 500 P/E ratio of 17.7. Shares are up 14.5% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.
TheStreet Ratings rates
Amgen
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
- You can view the full Amgen Ratings Report.
On the positive front,
(
), up 51.3%,
Bacterin International Holdings
(
), up 20.0%,
(
), up 18.9% and
(
), up 18.2% , were all gainers within the drugs industry with
Valeant Pharmaceuticals International
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null